turning to our acquired businesses, the rapid execution initiatives under our 180 day growth revitalization plan are delivering tangible results and the benefits are progressively taking hold. On pricing, net price realization scaled to 120 basis points, up from 90 basis points last quarter, giving us further confidence that we will meet or exceed ? the 150 basis points over the next several quarters. On reagent rental compliance, our dedicated team is now addressing the global opportunity we identified. We expect to begin recapturing low to mid single digit millions of dollars per quarter, beginning in the fourth quarter and further adding to our opportunity ahead. In biosciences, local manufacturing in China came online ahead of schedule and was a key driver of the geography's return to growth. Looking ahead versus first half levels, local manufacturing, better execution, including faster export license approvals, and DRG analyzing into the baseline should together add about 200 basis points to biosciences growth over the next several quarters. Together, these actions have driven a clear inflection in growth. Our guidance implies 5% constant currency growth for our acquired businesses in the second half of 2026, with further runway to grow faster as these benefits continue to take hold. In addition, as part of a second phase of execution initiatives, we have now launched a localization initiative for our microbiology portfolio in China, which we expect to further augment growth in the quarters ahead. In parallel, the first full tranche of revenue synergies from our combination is now entering our results. ? With the BackTech FXI culture system and the Fax Discover A7 flow cytometer now launched, service plan attachment rising and new digital channels beginning to generate incremental sales. The fourth quarter marks the first in which all of these levers contribute together. With this progress, we firmly remain on track to deliver $50 million of revenue synergies in 2026. We're also applying our launch excellence model to our Unclarity HPV self-collection kit launch and molecular diagnostics. This FDA cleared solution enables individuals to collect their own sample at home, expanding access for the more than 24 million people in the US who are unscreened or underscreened for HPV, the cause of nearly all cervical cancers. We recently announced commercial partnerships for this breakthrough innovation with Quest Diagnostics and LabCore, who are adding it to their test menus with revenue expected to begin next year as samples are processed on our BD Core platform. Turning to legacy waters, ? a strategy across commercial execution, new product innovation, and deliberate expansion into faster growing adjacencies continues to play out successfully, delivering the high single digit growth we committed to at our investor day in early 2025. Over the past eight quarters, we have averaged approximately 8% organic constant currency growth, well ahead of 2% for the life science tools market and 5% for our closest peer. peer. We remain in the middle innings of the instrument replacement cycle, which continues to drive strong instrument growth. Separate from replacement, our idiosyncratic growth drivers across GLP1s, BFAS testing, India Genetics, and Biologics are still scaling. We continue to estimate they will add more than 200 basis points of annual growth through 2030. China has also improved significantly this year with organic growth of 11% year to date, making ? it accretive to company growth once again. ? The resurgence in China, biotech, CRO, and CDMO activity is becoming a structural tailwind, reinforced by China's latest five year plan and its bold 2030 2030 targets for biopharma. With these attractive and diversified sources of growth, Legacy Waters is a durable, high single digit grower. In addition, new growth vectors are set to add further momentum across pharma, reshoring, semiconductor and data center testing, and AI-driven demand in the quarters ahead. Given strong conversion trends, we also expect our empowered subscription transition to turn neutral to growth next year. For pharma reshoring, we have already received double-digit millions of dollars in orders tied to new sites as projects move from construction into instrument outfitting. In semiconductor and data testing, growth is accelerating in the material sciences division as chip production output and data center build-out scale further. Next year, we also expect to increasingly capture this opportunity in analytical sciences. Across both divisions, we serve an addressable market of approximately $600 million, growing double digits with clear room to gain share. For AI-driven demand, ? I will now cover this in three parts: ? the shift we are seeing with our customers, the strategy that positions waters to lead, and the growth it is unlocking in our portfolio. Over the past several months, I've spent significant time with our pharma customers. Artificial intelligence has become a key topic in these conversations. Realizing its benefits has quickly become a key enterprise priority for our customers, not just in research, ? but in development and quality control as ? well. At Waters, we manage this fast emerging space with a weekly AI council, which I chair and which reaches into the organization. Our customers view waters as a key partner in the AI transformation of the lab, and for good reason. Over several years, we have developed a clear strategy and launched leading solutions that leverage our unique market position in several ways. In research, our customers are using AI to supercharge discovery output. Like others, our strategy advances lab in the loop science by enabling agents to autonomously run AI designed experiments on our instruments. Where waters stands apart is what happens next. Our cloud-based platform answers a clear customer need, allowing this work to transfer seamlessly between labs globally and move downstream into Empower on a single platform with no handoff. ? In development, our customers' objective is to accelerate drug development and streamline regulatory submission. Empower is the compliance system of record for regulated chromatography, holding terabytes of validated data for each customer, a data set that is unique in our industry. As a central part of our strategy, we are deploying empowered AI features that unlock insights from this data to increase productivity and to improve accuracy. In QC, ? our customers' objective is to boost efficiency and improve accuracy while maintaining compliance. Here, our strategy is bringing AI, ML, and automation directly into the validated environment on our customers, on our Empower platform, preserving data integrity with a complete audit trail for regulators. This matters. This matters because data remains compliant only while it stays within Empower. That is why these capabilities must live inside our platform and be trusted to keep data safe. Together, this positions waters for distinct sources of AI-driven growth, spanning discovery, development, and QC, enabling growth across both higher volume and higher value vectors. Let me explain what that means in practice. ? The first is higher volume. In research, AI is already generating more hypotheses and creating more physical samples that must be separated, purified, and measured, driving more LCMS runs and greater column consumption. This demand is coming from two sources. Our instrument systems and separation solutions are placed in AI enabled labs at eight of the top 10 global pharma companies where experiment volume is rising. At the same time, a new class of customers is emerging. AI-native biotech companies are reimagining the lab from a clean sheet using AI to create de novo labs run by agents and selecting waters instruments to test the molecules ? that their models design. So far, in 2026, dozens of these companies in the US and China have become first-time waters customers. Last month, ? we took a step in supporting these customers with the launch of Water's AI Link, which aligns our instruments with Anthropic's model context protocol and model hardware standard. This reduces the time to connect AI agents to our instruments from weeks to hours and strengthens our leading role as labs move towards AI directed autonomous operation. This progress is particularly valuable as we have the widest portfolio of instruments for bioanalytical characterization across LCMS, light scattering, flow, DMS, and other techniques. In downstream applications, we are connecting these instruments through automated workflows that run as one process from sample to readout with empower, then bringing the data together. ? The same dynamic is lifting our consumables' growth. Max peak premiere columns are unique in the industry because their innovative surface technology eliminates hours of column conditioning time and reduces cleaning time in between injections. It also delivers sharper peaks and more accurate results from less sample. This is exactly what these AI workflows need most higher throughput, efficient sample use, and better data to train models. And it is one reason why both large farmer and tech buyers are choosing waters as they scale. The second is higher value. In late stage development and manufacturing QC, we are turning Empower into a connected, intelligent platform consistent with the strategy we laid out at our March 2025 Investor Day. We're bringing new AI enabled features to more than ? to the more than 500,000 Empower users who support the release of our over 80% of medicines globally, delivered by a premium tier in our subscription model. ? For the first time, these features make our unique data set a core part of the Empower product, turning compliant data that has long sat within Empower into a source of insight and value. We launched the first of these AI-powered anomaly detection in February of 2025. Last week we announced AI-powered peak integration, which automates one of the most manual and variable steps in chromatography. ? In a pilot with a large pharma customer, it reduced manual interventions by up to 95%, with 76% greater accuracy and 72% lower user-to-user variability. Several more AI applications are set to launch in the first half of 2027, which will accelerate column selection, method development, and release timelines. Each new capability makes empower more valuable ? to the labs already running it and is accelerating the transition to our subscription model. On top of that transition, the premium tier these features sit on is expected to generate a substantial increase in revenue per lab over time. Beyond our customers, AI is also changing how we run waters, most visibly in our integration. AI tools helped us complete our organizational restructuring and reach our target cost structure well ahead of plan, a key reason why we are set to achieve the $200 million of run rate cost savings more than two years ahead of schedule. AI is also accelerating procurement savings with DataCube negotiation advisors that consolidate spend across our organic and acquired businesses. This lets us identify savings instantly, optimize pricing, and move contracts from BD to waters faster. Finally, we have integrated AI into our products and services, launching 10 Lighthouse programs several years ago to apply AI and machine learning across the portfolio. One example is our service AI Advisor, which turns decades of free from service notes into answers that engineers and customers can access in everyday language. It has saved millions of dollars in parts, improved fixed rates by 10%, and avoided hundreds of unnecessary service visits, making our already differentiated service even stronger. We've also built intelligence directly into our instruments. Our Alliance ISHPLC system, for example, uses guided setup, automated checks, and built-in error detection to prevent up to 40% of common user errors before they affect the result.
Passages & reports (70) 10:02 turning to our acquired businesses, the rapid execution initiatives under our 180 day grow… Report 10:22 quarter, giving us further confidence that we will meet or exceed Report 10:26 the Report 10:26 150 basis points over the next several quarters. On reagent rental compliance, our dedicat… Report 10:47 In biosciences, local manufacturing in China came online ahead of schedule and was a key d… Report 11:07 add about 200 basis points to biosciences growth over the next several quarters. Together,… Report 11:27 to grow faster as these benefits continue to take hold. In addition, as part of a second p… Report 11:46 full tranche of revenue synergies from our combination is now entering our results. Report 11:51 With Report 11:52 the BackTech FXI culture system and the Fax Discover A7 flow cytometer now launched, servi… Report 12:12 firmly remain on track to deliver $50 million of revenue synergies in 2026. We're also app… Report 12:31 home, expanding access for the more than 24 million people in the US who are unscreened or… Report 12:51 to their test menus with revenue expected to begin next year as samples are processed on o… Report 13:00 a Report 13:01 strategy across commercial execution, new product innovation, and deliberate expansion int… Report 13:20 organic constant currency growth, well ahead of 2% for the life science tools market and 5… Report 13:40 GLP1s, BFAS testing, India Genetics, and Biologics are still scaling. We continue to estim… Report 13:59 it Report 13:59 accretive to company growth once again. Report 14:02 The Report 14:03 resurgence in China, biotech, CRO, and CDMO activity is becoming a structural tailwind, re… Report 14:22 digit grower. In addition, new growth vectors are set to add further momentum across pharm… Report 14:42 growth next year. For pharma reshoring, we have already received double-digit millions of … Report 15:02 and data center build-out scale further. Next year, we also expect to increasingly capture… Report 15:21 I Report 15:22 will now cover this in three parts: Report 15:24 the Report 15:24 shift we are seeing with our customers, the strategy that positions waters to lead, and th… Report 15:44 quickly become a key enterprise priority for our customers, not just in research, Report 15:49 but Report 15:49 in development and quality control as Report 15:51 well. Report 15:52 At Waters, we manage this fast emerging space with a weekly AI council, which I chair and … Report 16:11 launched leading solutions that leverage our unique market position in several ways. In re… Report 16:31 stands apart is what happens next. Our cloud-based platform answers a clear customer need,… Report 16:47 In Report 16:47 development, our customers' objective is to accelerate drug development and streamline reg… Report 17:06 central part of our strategy, we are deploying empowered AI features that unlock insights … Report 17:17 our Report 17:17 customers' objective is to boost efficiency and improve accuracy while maintaining complia… Report 17:37 This matters. This matters because data remains compliant only while it stays within Empow… Report 17:57 development, and QC, enabling growth across both higher volume and higher value vectors. L… Report 18:06 The Report 18:06 first is higher volume. In research, AI is already generating more hypotheses and creating… Report 18:26 are placed in AI enabled labs at eight of the top 10 global pharma companies where experim… Report 18:46 instruments to test the molecules Report 18:48 that Report 18:49 their models design. So far, in 2026, dozens of these companies in the US and China have b… Report 18:58 we Report 18:58 took a step in supporting these customers with the launch of Water's AI Link, which aligns… Report 19:18 autonomous operation. This progress is particularly valuable as we have the widest portfol… Report 19:37 process from sample to readout with empower, then bringing the data together. Report 19:44 The Report 19:44 same dynamic is lifting our consumables' growth. Max peak premiere columns are unique in t… Report 20:04 AI workflows need most higher throughput, efficient sample use, and better data to train m… Report 20:24 consistent with the strategy we laid out at our March 2025 Investor Day. We're bringing ne… Report 20:33 to Report 20:33 the more than 500,000 Empower users who support the release of our over 80% of medicines g… Report 20:48 For Report 20:48 the first time, these features make our unique data set a core part of the Empower product… Report 21:08 one of the most manual and variable steps in chromatography. Report 21:11 In Report 21:11 a pilot with a large pharma customer, it reduced manual interventions by up to 95%, with 7… Report 21:31 accelerate column selection, method development, and release timelines. Each new capabilit… Report 21:38 to Report 21:38 the labs already running it and is accelerating the transition to our subscription model. … Report 21:57 integration. AI tools helped us complete our organizational restructuring and reach our ta… Report 22:17 DataCube negotiation advisors that consolidate spend across our organic and acquired busin… Report 22:37 AI and machine learning across the portfolio. One example is our service AI Advisor, which… Report 22:57 making our already differentiated service even stronger. We've also built intelligence dir… Report